MRC1 and neoplasm: However, several studies have indicated that MMR deficiency—which potently protects tumor cells against TMZ irrespective of their MGMT status11,12—can emerge in response to treatment with the Stupp protocol and presents with some frequency in recurrent tumors.14,15 It is therefore relevant for clinical decision-making and would seem to exclude the further use of TMZ.